Trials / Completed
CompletedNCT03648476
Intervention to Change Attributions That Are Negative (ICAN)
Intervention to Change Attributions That Are Negative (ICAN): a New Approach to Reducing Anger and Aggression After Brain Injury
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 28 (actual)
- Sponsor
- Indiana University · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
ICAN is the first treatment to target hostile attributions after TBI, making it a novel anger/ aggression management approach in this population. This is a randomized waitlist control trial. The length of time in the trial is approximately 15 weeks and the intervention is 6 weeks long.
Detailed description
ICAN is the first treatment to target hostile attributions after TBI, making it a novel anger/ aggression management approach in this population. Since the investigator's prior research shows that stronger hostile attributions are associated with poorer perspective taking,39 ICAN employs a unique perspective-positioning technique to train perspective taking and reduce hostile attributions. After recalling a personal situation in which others' ambiguous actions led to an unpleasant outcome, participants will explore different perspectives: sitting or standing in one position, s/he will explore his or her own thoughts and feelings (self-perspective), then move to a different position to experience the other person's perspective, eliciting their thoughts and feelings. In 40 participants with TBI, we will conduct a Phase I, randomized waitlist controlled trial with 4 data collection points: Baseline; Week 1; Week 8 (post-treatment for ICAN; post-wait period for WLC); Week 15 (WLC post-treatment).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BEHAVIORAL | ICAN | A 6-week group therapy sessions once a week for 90-120 minutes. |
Timeline
- Start date
- 2018-11-02
- Primary completion
- 2020-11-23
- Completion
- 2021-01-11
- First posted
- 2018-08-27
- Last updated
- 2022-05-23
- Results posted
- 2022-05-23
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT03648476. Inclusion in this directory is not an endorsement.